Avistone Biotechnology Co., Ltd.
Quick facts
Phase 3 pipeline
- Pemetrexed plus Carboplatin or Cisplatin · Oncology
Pemetrexed inhibits multiple folate-dependent enzymes involved in nucleotide synthesis, while carboplatin or cisplatin are platinum-based agents that cross-link DNA, together inducing cancer cell death. - PLB1004
PLB1004 is a small molecule inhibitor targeting a specific molecular pathway in cancer or immune-related disease.
Phase 1 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Avistone Biotechnology Co., Ltd. portfolio CI brief
- Avistone Biotechnology Co., Ltd. pipeline updates RSS
Frequently asked questions about Avistone Biotechnology Co., Ltd.
What is Avistone Biotechnology Co., Ltd.'s pipeline?
Avistone Biotechnology Co., Ltd. has 2 drugs in Phase 3, 0 in Phase 2, 2 in Phase 1. Late-stage candidates include Pemetrexed plus Carboplatin or Cisplatin, PLB1004.
Related
- Sector hub: All tracked pharma companies